Russell Investments Group Ltd. lessened its stake in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 19.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,979 shares of the company’s stock after selling 20,176 shares during the quarter. Russell Investments Group Ltd.’s holdings in Endo International were worth $1,412,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of ENDP. Bank of New York Mellon Corp boosted its holdings in Endo International by 13.2% during the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after buying an additional 284,599 shares in the last quarter. New York State Teachers Retirement System boosted its holdings in Endo International by 27.0% during the second quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock worth $3,366,000 after buying an additional 75,844 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its holdings in Endo International by 1.0% during the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after buying an additional 10,600 shares in the last quarter. Sivik Global Healthcare LLC bought a new stake in Endo International during the second quarter worth approximately $1,697,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Endo International by 1,209.0% during the third quarter. Nisa Investment Advisors LLC now owns 26,179 shares of the company’s stock worth $441,000 after buying an additional 24,179 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.
A number of analysts recently weighed in on ENDP shares. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Monday, September 24th. BidaskClub cut shares of Endo International from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Canaccord Genuity upgraded shares of Endo International from a “hold” rating to a “buy” rating and raised their target price for the stock from $16.00 to $20.00 in a report on Friday, November 9th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a report on Monday, August 20th. Finally, Morgan Stanley raised their target price on shares of Endo International from $7.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, August 17th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $15.32.
In related news, Director Nancy J. Hutson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $12.83, for a total value of $128,300.00. Following the completion of the transaction, the director now owns 49,970 shares of the company’s stock, valued at approximately $641,115.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.
Endo International stock opened at $11.57 on Friday. Endo International PLC has a 52 week low of $5.27 and a 52 week high of $18.50. The company has a market capitalization of $2.60 billion, a P/E ratio of 3.99, a PEG ratio of 4.25 and a beta of 0.35.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.12. Endo International had a negative net margin of 37.82% and a positive return on equity of 1,348.52%. The firm had revenue of $745.00 million during the quarter, compared to analyst estimates of $694.93 million. During the same quarter last year, the business posted $0.91 EPS. The company’s revenue was down 5.3% on a year-over-year basis. Analysts forecast that Endo International PLC will post 2.73 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Endo International PLC (ENDP) Shares Sold by Russell Investments Group Ltd.” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/12/08/endo-international-plc-endp-shares-sold-by-russell-investments-group-ltd.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Further Reading: Hedge Funds – Risk or Reward?
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.